$IMMU stair steps 5 months
Upper bollie $6.63
Nasdaq
$IMMU stair steps 5 months
Upper bollie $6.63
Nasdaq GM
Website
Last ten trades
10-Q 2/10/17
80% x 100% Strong Buy
Shares Outstanding 106.08M
Float 89.45M
% Held by Insiders 6.84%
% Held by Institutions 43.70%
Shares Short 3 21.88M
Short Ratio 4.12
Short % of Float 21.98%
Shares Short (prior month) 23.57M
Stock technical analysis
News
and filings
Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and epratuzumab, a humanized antibody that targets CD22, an antigen found on the surface of B lymphocytes. Its early-stage products include IMMU-114, a novel humanized antibody for the treatment of patients with B-cell and other cancers; Milatuzumab, a humanized monoclonal antibody targeting tumors that expresses the CD74 antigen, which is present on various hematological tumors and solid cancers; Veltuzumab, a humanized monoclonal antibody targeting CD20 receptors on B lymphocytes for the treatment of non-Hodgkin lymphoma and autoimmune diseases; and Yttrium-90-Labeled Epratuzumab Tetraxetan, a radiolabeled anti-CD22 investigational product. The company also provides LeukoScan, a diagnostic imaging product for diagnostic imaging to determine the location and extent of infection/inflammation in bone. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has a research collaboration with The Bayer Group to study epratuzumab as a thorium-227-labeled antibody. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.
Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A Jolt for Ontario's Life Sciences Sector Ah, there's fresh energy in the air up north, folks. Ontario's dishing out a solid $1.7 million to give Piramal Pharma Solutions' Aurora facility a serious facelift. This isn't just about shiny new labs. It's about staking a claim, saying, "We're serious players on the global stage." They're not just upgrading infrastructure...
Continue Reading
Breaking Barriers: El Mansouri's Historic Appointment Fatima Ezzahra El Mansouri is now steering the ship as Morocco's first female Prime Minister, a milestone that's taken far too long to reach. After the dust settled from the September 23 legislative elections, El Mansouri emerged from the Authenticity and Modernity Party (PAM) with 97 seats in tow. It's a pivotal...
Continue Reading
Golf Reinvented: Kohler Hosts No Tees Tour Talk about flipping the script, eh? Kohler's teaming up with the No Tees Tour to host an innovative golfing showdown at The Baths of Blackwolf Run, starting October 1. This isn't your grandpa's golf tour. We're talking fast-paced, head-to-head chipping duels that ditch the long drives for surgical precision. The idea's inspired...
Continue Reading
A Dive into King Technology's Strategic Move King Technology is making waves like a cannonball in the kiddie pool with its new $17 million manufacturing and distribution center in St. Peters, Missouri. This isn't just pocket change being thrown around here—it's a calculated step in their game plan to boost efficiency and lock in some serious distribution prowess across...
Continue Reading
Alright, folks, let's talk Fitness Connection and their fresh move that's shaking things up in North Houston. So, they're not just sticking around; they're tuning up a beefy new 45,000-square-foot club right where Greenspoint Mall once stood. There's a $150 million overhaul going on at this site now known as CityNorth, and Fitness Connection plans to be right at the heart...
Continue Reading
Court Orders Health Coverage Amid Creamery Dispute Good grief! Just when you think you've seen all the punches the corporate world can throw, something like this comes along. The court's declaration that Dairy Farmers of America (DFA) must keep providing health care to members of Teamsters Local 597 is pushing back the tides for workers at the St. Albans Creamery. This...
Continue Reading
Eyeing the Future in South Miami Real Estate Well, folks, things are heating up in South Miami’s real estate scene, and it’s not something investors want to snooze through. Alta Development, with its decades-long track record, has hurled SoMi Walk into the market ring. This isn't just another dime-a-dozen project. It's a behemoth—standing at 16 stories and posing as...
Continue Reading
An Airman’s Mission of Building Legacies When you think of flooring, 'admired CEOs' probably don’t top the list. Yet here’s Bryan Park, an ex-Air Force veteran, shaking things up and earning a nod from the Denver Business Journal. Named one of the Most Admired CEOs of 2026, Park has taken what began as a small flooring operation and turned it into a national...
Continue Reading
Skiptown Marches into the Heart of Texas A move into Texas? Now that's got potential written all over it. Skiptown's making waves by dropping anchor in Austin with a five-unit franchise agreement. We're talking modern dog daycare and more, right in the heart of Central Texas. First up, fall 2027 is when you can circle the calendar. Expect to see more locations sprout up...
Continue Reading
They don't hand out "Attorney of the Year" awards to just anyone. Joe Richardson snagged this title from the Richard T. Fields Bar Association not just because he's part of McCune Law Group, but because he's been shaking up the legal arena with his advocacy and leadership. Let's peel back why this matters not only within his circles but for the broader legal community...
Continue Reading
Top 5 Most Recently Viewed Articles
Endeavour Mining's Share Buyback Announcement Endeavour Mining plc Endeavour Mining plc (LSE:EDV, TSX:EDV) detailed an exciting development with the purchase of shares from Stifel Nicolaus Europe Limited. This transaction highlights the company's strategy to enhance shareholder value through stock buybacks. Details of the Share Purchase Share Purchase Overview
Continue Reading
Meijer snagged some serious kudos back when the U.S. Environmental Protection Agency's GreenChill Program handed out awards, naming it the champ of refrigerant emissions rates among partners nationwide. This wasn’t just a one-off—nope, it was four years running, highlighting Meijer's deep-seated pledge to keep things green. Back in 2012, they jumped into the EPA’s...
Continue Reading
Two Harbors Investment Corp. Earnings Release Announcement Two Harbors Investment Corp. (NYSE: TWO), an innovative player in the real estate investment trust sector, is set to unveil its financial results for the third quarter of 2024 after the market bell on the day before the earnings call. This follows their previous earnings announcement at the close of Q2, which...
Continue Reading
Critical Insights on Long-Tailed Macaques A recent article has emerged that critically evaluates the long-tailed macaque population, specifically addressing the methodology used in global assessments. Published in a distinguished journal, the findings challenge the current stance taken by prominent conservation organizations regarding the species' vulnerability. The Deep...
Continue Reading
Clouds Gather Over Insulet Corporation Nothing quite stirs up the market like a class action lawsuit, and today it's Insulet Corporation's turn in the spotlight. So, if you’re holding Insulet shares—brace yourself. Bronstein, Gewirtz & Grossman, LLC, they're the legal warriors drawing swords against Insulet (NASDAQ:PODD). The story is about alleged missteps that seem...
Continue Reading